Company
Seelos Therapeutics
NASDAQ: SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company’s robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York.
34 stories
Companies are starting to bet big on psychedelic drugs to treat US mental health epidemic
Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression
Seelos Therapeutics initiates preclinical study of SLS-004 in Parkinson’s disease
The study will focus on repression of the SNCA gene, which has been implicated as a highly significant risk factor in Parkinson's
Seelos Therapeutics to host key opinion leader call to discuss unmet medical needs in suicide and depression
The discussion will also focus on the group's SLS-002 intranasal racemic ketamine drug aimed at Acute Suicidal Ideation and Behavior (ASIB) in patients with major depressive disorder
Seelos Therapeutics' trehalose gets Rare Pediatric Disease Designation (RPDD) for treatment of Sanfilippo syndrome
RPDD is an incentive program which provides priority review vouchers to encourage the development of new therapies to prevent and treat rare pediatric diseases
Seelos Therapeutics shares push higher as it reveals patent news for SLS-005 drug
The group is focused on advancing therapeutics to address unmet medical needs for central nervous system disorders and other rare conditions
Seelos Therapeutics shares gain as it receives Orphan Drug designation for SLS-005
ODD allows companies developing rare disease treatments to access various incentives like tax credits for qualified clinical testing
Seelos gets renewed Buy rating, $8 price target from Roth ahead of study data for its ketamine depression drug
Roth said the Phase 1 trial of flagship drug SLS-002 represents a “potential blockbuster market opportunity”
Seelos' ketamine depression drug on track as company stresses importance of mental health during coronavirus pandemic
The New York company expects to release additional safety data on the Phase I studies of SLS-002 in the second quarter
Seelos Therapeutics "extremely pleased" with side effect data from Phase I studies of SLS-002
Some of the key highlights of the interim vital signs adverse events data, included that no serious adverse events related to vital signs were observed
Seelos to design Sanfilippo syndrome study of its drug Trehalose in Europe following regulatory guidance
The open-label, non-placebo controlled study will evaluate Trehalose for patients with Sanfilippo syndrome in the EU
Seelos receives Notice of Allowance from US patent office for Parkinson’s disease drug SLS-007
It covers the composition of matter comprising at least one peptide that inhibits the protein alpha-synuclein
Seelos unveils additional data showcasing the safety of its ketamine depression drug
The data demonstrated that 30mg, 60mg, 75mg and 90mg doses have been generally safe and well-tolerated
Seelos has catalysts for its ketamine depression drug, multiple shots on goal with a strong pipeline
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
Seelos Therapeutics looks to raise $4.3M in latest offering
Under the terms, 6,666,667 shares of Seelos stock will be sold at a price of $0.75 per share
Seelos Therapeutics to test Parkinson's Disease drug SLS-007 in gene therapy study
SLS-007 in the company's second gene therapy program to fight the neurodegenerative disorder
Seelos Therapeutics wins key meeting with European regulator to propose Trehalose study for Sanfilippo syndrome
It has set up a meeting with the European Medicines Agency in March 2020 for scientific advice and assistance over a clinical study in Europe
Archive
NA Proactive news snapshot: Chemistree, Aequus, Ceylon Graphite, Para Resources UPDATE …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Seelos Therapeutics releases interim study data validating the safety of its ketamine depression drug
It showed 60 milligrams of SLS-002 to be safe and well tolerated as a monotherapy or with an oral antidepressant
Seelos to seek FDA guidance on Phase III trial for SLS-002 ketamine depression drug
It will seek guidance from the FDA in March for an adaptive Phase III trial of SLS-002
Roth applauds Seelos' shift towards major depressive disorder with SLS-002; rates shares 'Buy'
Roth analysts view MDD as a "more substantial commercial opportunity", according to a note
Investments and investor services
Seelos Therapeutics notches key advance in US patent process for Trehalose
Trehalose is an investigational molecule which shows promise in treating Sanfilippo syndrome and other neurodegenerative conditions
Seelos starts dosing in Phase I PK/PD study of SLS-002 intranasal ketamine depression drug
Preliminary data from the profile study is expected in the first quarter of 2020
Seelos starts initial dosing in Phase 1 study of its SLS-002 intranasal ketamine depression drug
Preliminary data from the study is expected in the first quarter of 2020
NA Proactive news snapshot: BioPorto, Great Panther Mining, Capstone Turbine, Parallax Health Sciences UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Seelos stock soars after its SLS-002 intranasal ketamine depression drug granted fast track status by FDA
This boosts the drug's prospects as Seelos will work closely with the FDA to finalize the protocol for the proof of concept study and its clinical development
Seelos Therapeutics updates investors on 3Q drug development, plans studies for Sanfilippo syndrome, PTSD treatments
The IND application for its Sanfilippo syndome drug was accepted by the FDA, and it plans to file another IND for a potential pediatric esophagitis treatment
Investments and investor services
Roth gives thumbs up to Seelos Therapeutics new plan for SLS-002 in treating suicidality
Analyst Yasmeen Rahimi has a Buy recommendation and $8 price target on Seelos stock, which presently trades in the $0.93 range
NA Proactive news snapshot: Seelos Therapeutics, Namaste Technologies, Codebase Ventures, Orsu Metals …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Seelos Therapeutics plans to study SLS-002 in patients at risk of suicide
The New York-based company also said it is amending its agreement with Vyera Pharmaceuticals for the development of SLS-002
Seelos Therapeutics names industry veteran Scott Applebaum as lead strategic regulatory consultant
Applebaum has more than two decades of experience working with public and private companies handling regulatory matters
Seelos Therapeutics launches $6.7 million direct share offering with certain institutional investors
The company intends to use the net proceeds for general corporate purposes and to advance the development of its product candidates
Archive
NA Proactive news snapshot: Medexus Pharmaceuticals, Pressure BioSciences, Next Green Wave, Ventura Cannabis, Biocept UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Seelos Therapeutics says FDA accepts Investigation New Drug application for trehalose, can proceed with proposed Sanfilippo patients clinical trial
Seelos’ chief medical officer commented: “We are very pleased to have received the acceptance letter and continue to work closely with the FDA to finalize the details of the analysis methodology"